IBDEI11C ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16643,2)
 ;;=^5063434
 ;;^UTILITY(U,$J,358.3,16644,0)
 ;;=Z85.72^^88^880^98
 ;;^UTILITY(U,$J,358.3,16644,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16644,1,3,0)
 ;;=3^Personal Hx of Non-Hodgkin Lymphomas
 ;;^UTILITY(U,$J,358.3,16644,1,4,0)
 ;;=4^Z85.72
 ;;^UTILITY(U,$J,358.3,16644,2)
 ;;=^5063436
 ;;^UTILITY(U,$J,358.3,16645,0)
 ;;=Z85.79^^88^880^88
 ;;^UTILITY(U,$J,358.3,16645,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16645,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Lymphoid,Hematpoetc & Rel Tissue
 ;;^UTILITY(U,$J,358.3,16645,1,4,0)
 ;;=4^Z85.79
 ;;^UTILITY(U,$J,358.3,16645,2)
 ;;=^5063437
 ;;^UTILITY(U,$J,358.3,16646,0)
 ;;=Z85.820^^88^880^77
 ;;^UTILITY(U,$J,358.3,16646,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16646,1,3,0)
 ;;=3^Personal Hx of Malig Melanoma of Skin
 ;;^UTILITY(U,$J,358.3,16646,1,4,0)
 ;;=4^Z85.820
 ;;^UTILITY(U,$J,358.3,16646,2)
 ;;=^5063441
 ;;^UTILITY(U,$J,358.3,16647,0)
 ;;=Z85.828^^88^880^92
 ;;^UTILITY(U,$J,358.3,16647,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16647,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Skin
 ;;^UTILITY(U,$J,358.3,16647,1,4,0)
 ;;=4^Z85.828
 ;;^UTILITY(U,$J,358.3,16647,2)
 ;;=^5063443
 ;;^UTILITY(U,$J,358.3,16648,0)
 ;;=Z85.71^^88^880^72
 ;;^UTILITY(U,$J,358.3,16648,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16648,1,3,0)
 ;;=3^Personal Hx of Hodgkin Lymphoma
 ;;^UTILITY(U,$J,358.3,16648,1,4,0)
 ;;=4^Z85.71
 ;;^UTILITY(U,$J,358.3,16648,2)
 ;;=^5063435
 ;;^UTILITY(U,$J,358.3,16649,0)
 ;;=Z65.8^^88^880^144
 ;;^UTILITY(U,$J,358.3,16649,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16649,1,3,0)
 ;;=3^Psychosocial Circumstance Related Problems
 ;;^UTILITY(U,$J,358.3,16649,1,4,0)
 ;;=4^Z65.8
 ;;^UTILITY(U,$J,358.3,16649,2)
 ;;=^5063185
 ;;^UTILITY(U,$J,358.3,16650,0)
 ;;=Z86.11^^88^880^109
 ;;^UTILITY(U,$J,358.3,16650,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16650,1,3,0)
 ;;=3^Personal Hx of Tuberculosis
 ;;^UTILITY(U,$J,358.3,16650,1,4,0)
 ;;=4^Z86.11
 ;;^UTILITY(U,$J,358.3,16650,2)
 ;;=^5063461
 ;;^UTILITY(U,$J,358.3,16651,0)
 ;;=Z86.13^^88^880^76
 ;;^UTILITY(U,$J,358.3,16651,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16651,1,3,0)
 ;;=3^Personal Hx of Malaria
 ;;^UTILITY(U,$J,358.3,16651,1,4,0)
 ;;=4^Z86.13
 ;;^UTILITY(U,$J,358.3,16651,2)
 ;;=^5063463
 ;;^UTILITY(U,$J,358.3,16652,0)
 ;;=Z86.73^^88^880^106
 ;;^UTILITY(U,$J,358.3,16652,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16652,1,3,0)
 ;;=3^Personal Hx of TIA & Cereb Infrc w/o Residual Deficits
 ;;^UTILITY(U,$J,358.3,16652,1,4,0)
 ;;=4^Z86.73
 ;;^UTILITY(U,$J,358.3,16652,2)
 ;;=^5063477
 ;;^UTILITY(U,$J,358.3,16653,0)
 ;;=Z86.79^^88^880^69
 ;;^UTILITY(U,$J,358.3,16653,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16653,1,3,0)
 ;;=3^Personal Hx of Circulatory System Diseases
 ;;^UTILITY(U,$J,358.3,16653,1,4,0)
 ;;=4^Z86.79
 ;;^UTILITY(U,$J,358.3,16653,2)
 ;;=^5063479
 ;;^UTILITY(U,$J,358.3,16654,0)
 ;;=Z91.040^^88^880^57
 ;;^UTILITY(U,$J,358.3,16654,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16654,1,3,0)
 ;;=3^Latex Allergy Status
 ;;^UTILITY(U,$J,358.3,16654,1,4,0)
 ;;=4^Z91.040
 ;;^UTILITY(U,$J,358.3,16654,2)
 ;;=^5063607
 ;;^UTILITY(U,$J,358.3,16655,0)
 ;;=Z92.3^^88^880^73
 ;;^UTILITY(U,$J,358.3,16655,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16655,1,3,0)
 ;;=3^Personal Hx of Irradiation
 ;;^UTILITY(U,$J,358.3,16655,1,4,0)
 ;;=4^Z92.3
 ;;^UTILITY(U,$J,358.3,16655,2)
 ;;=^5063637
